Michael J Davies Selected Research

Metformin (Glucophage)

1/2018	Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
6/2016	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.
8/2012	Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
6/2011	Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.
7/2010	Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
4/2010	Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.
3/2009	Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael J Davies Research Topics

Disease

53	Inflammation (Inflammations) 01/2022 - 01/2002
43	Type 2 Diabetes Mellitus (MODY) 01/2018 - 05/2005
37	Atherosclerosis 01/2022 - 04/2002
17	Hypoglycemia (Reactive Hypoglycemia) 01/2018 - 12/2005
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 05/2004
9	Body Weight (Weight, Body) 01/2021 - 02/2008
8	Hypertension (High Blood Pressure) 01/2018 - 08/2004
7	Asthma (Bronchial Asthma) 03/2011 - 04/2004
7	Coronary Disease (Coronary Heart Disease) 05/2006 - 10/2003
6	Infections 01/2021 - 10/2005
6	Neoplasms (Cancer) 01/2017 - 01/2002
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 01/2013
5	Cataract (Cataracts) 10/2016 - 07/2002
5	Atherosclerotic Plaque (Atheroma) 05/2015 - 03/2003
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 01/2021
3	Disease Progression 01/2022 - 11/2003
3	Multiple Sclerosis 01/2022 - 01/2021
3	Necrosis 01/2021 - 09/2008
3	Fibrosis (Cirrhosis) 01/2021 - 01/2013
3	Weight Loss (Weight Reduction) 01/2018 - 08/2002
3	Insulin Resistance 01/2018 - 05/2002
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2017 - 07/2004
3	Infertility (Sterility) 10/2016 - 09/2003
3	Rupture 01/2016 - 02/2002
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 02/2009 - 07/2005
3	Hyperlipidemias (Hyperlipidemia) 06/2008 - 04/2006
2	Parkinson Disease (Parkinson's Disease) 01/2022 - 04/2002
2	Chronic Renal Insufficiency 01/2022 - 07/2010
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2021 - 11/2020
2	Reperfusion Injury 01/2021 - 12/2015
2	Weight Gain 01/2021 - 07/2004
2	Overweight 01/2021 - 01/2018
2	Heart Failure 08/2017 - 03/2015
2	Urinary Tract Infections (Urinary Tract Infection) 01/2017 - 06/2016

Drug/Important Bio-Agent (IBA)

29	Oxidants (Oxidizing Agents)IBA 01/2022 - 11/2003
28	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2002
24	Peroxidase (Myeloperoxidase)IBA 09/2021 - 05/2009
20	Sitagliptin Phosphate (Januvia)FDA Link 01/2017 - 12/2005
15	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 05/2002
15	LipidsIBA 01/2017 - 04/2002
14	Hypoglycemic Agents (Hypoglycemics)IBA 03/2015 - 11/2006
13	EnzymesIBA 01/2021 - 07/2002
11	oxidized low density lipoproteinIBA 01/2016 - 04/2003
9	Insulin (Novolin)FDA Link 01/2021 - 05/2002
8	Hypochlorous Acid (Hypochlorite)IBA 01/2021 - 09/2008
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2008
8	SymportersIBA 01/2021 - 06/2016
8	SodiumIBA 01/2021 - 06/2016
8	Peroxynitrous Acid (Peroxynitrite)IBA 01/2019 - 04/2007
8	CanagliflozinIBA 01/2018 - 06/2016
8	Triglycerides (Triacylglycerol)IBA 01/2017 - 05/2002
8	hypobromous acidIBA 06/2013 - 10/2005
8	CholesterolIBA 01/2013 - 04/2002
7	Metformin (Glucophage)FDA LinkGeneric 01/2018 - 03/2009
7	IonsIBA 10/2016 - 05/2004
6	SeleniumIBA 01/2021 - 12/2011
6	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2021 - 06/2016
6	LDL CholesterolIBA 01/2017 - 10/2003
6	LDL Lipoproteins (beta Lipoproteins)IBA 05/2015 - 04/2002
6	Ezetimibe (Zetia)FDA Link 06/2008 - 07/2005
6	Simvastatin (Zocor)FDA LinkGeneric 02/2007 - 07/2004
5	Pharmaceutical PreparationsIBA 01/2022 - 10/2008
5	Biological ProductsIBA 01/2021 - 10/2005
5	thiocyanateIBA 01/2021 - 11/2011
4	CytokinesIBA 09/2021 - 02/2014
4	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 01/2021 - 11/2020
4	Heme (Haem)IBA 01/2021 - 05/2009
4	glimepiride (Amarel)FDA LinkGeneric 01/2018 - 06/2011
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017 - 05/2011
4	MetalsIBA 10/2016 - 05/2004
4	Sulfhydryl Compounds (Thiols)IBA 12/2015 - 07/2009
4	Blood Proteins (Serum Proteins)IBA 11/2011 - 07/2005
4	GlycosaminoglycansIBA 08/2009 - 11/2003
3	Dimethyl FumarateIBA 01/2022 - 01/2021
3	PeroxidasesIBA 01/2021 - 07/2008
3	Tyrosine (L-Tyrosine)FDA Link 01/2019 - 11/2004
3	CarnosineIBA 01/2019 - 03/2007
3	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2016 - 11/2004
3	Crystallins (Crystallin)IBA 10/2016 - 11/2004
3	CollagenIBA 09/2016 - 01/2013
3	Cholesterol Esters (Cholesteryl Esters)IBA 01/2011 - 09/2003
3	IncretinsIBA 04/2010 - 11/2006
3	Fenofibrate (CiL)FDA LinkGeneric 06/2008 - 04/2006
3	Dipeptidyl-Peptidase IV InhibitorsIBA 02/2008 - 01/2006
3	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2006 - 12/2005
2	Muramidase (Lysozyme)IBA 01/2021 - 11/2005
2	CalciumIBA 01/2021 - 06/2012
2	Protective AgentsIBA 01/2020 - 03/2018
2	Fibronectins (Fibronectin)IBA 01/2020 - 01/2016
2	Laminin (Merosin)IBA 01/2019 - 04/2014
2	3-chlorotyrosineIBA 01/2019 - 01/2019
2	LeptinIBA 01/2018 - 05/2004
2	AdipokinesIBA 01/2018 - 05/2015
2	A-factor (Streptomyces)IBA 01/2017 - 11/2003
2	HDL CholesterolIBA 01/2017 - 06/2008
2	Superoxides (Superoxide)IBA 12/2015 - 01/2002
2	ChloraminesIBA 07/2015 - 01/2002

Therapy/Procedure

17	Therapeutics 01/2021 - 05/2004
8	Glycemic Control 01/2018 - 02/2008
3	Lenses 02/2014 - 11/2004